Ningbo Menovo Pharmaceutical Co (SHSE:603538) Cyclically Adjusted Revenue per Share: ¥4.28 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603538 Ningbo Menovo Pharmaceutical Co Ltd SHSE:603538
74 GF Score
Price ¥27.09
GF Value ¥17.40
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Ningbo Menovo Pharmaceutical Co Cyclically Adjusted Revenue per Share?

Ningbo Menovo Pharmaceutical Co SHSE:603538 +3.56% 74 Cyclically Adjusted Revenue per Share is ¥4.28 as of Jun. 2026. GuruFocus rates SHSE:603538 with a GF Score™ of 74/100 and a GF Value™ of ¥17.40 (Significantly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Ningbo Menovo Pharmaceutical Co's adjusted revenue per share for the three months ended in Jun. 2026 was ¥2.128. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ¥4.28 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Ningbo Menovo Pharmaceutical Co's average Cyclically Adjusted Revenue Growth Rate was 7.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-27), Ningbo Menovo Pharmaceutical Co's current stock price is ¥27.09. Ningbo Menovo Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ¥4.28. Ningbo Menovo Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is 6.33.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Ningbo Menovo Pharmaceutical Co was 15.01. The lowest was 1.87. And the median was 3.55.


Ningbo Menovo Pharmaceutical Co  (SHSE:603538) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Ningbo Menovo Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=27.09/4.28
=6.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Ningbo Menovo Pharmaceutical Co was 15.01. The lowest was 1.87. And the median was 3.55.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Ningbo Menovo Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms


Ningbo Menovo Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Ningbo Menovo Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ningbo Menovo Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Ningbo Menovo Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 3.89 4.12

Ningbo Menovo Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 4.05 4.12 4.16 4.28

SHSE:603538 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Ningbo Menovo Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ningbo Menovo Pharmaceutical Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ningbo Menovo Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Ningbo Menovo Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


SHSE:603538
74GF Score
Ningbo Menovo Pharmaceutical Co Ltd SHSE:603538
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ningbo Menovo Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ningbo Menovo Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=2.128/116.0564*116.0564
=2.128

Current CPI (Jun. 2026) = 116.0564.

Ningbo Menovo Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.700 102.400 0.793
201612 0.642 102.600 0.726
201703 0.560 103.200 0.630
201706 0.860 103.100 0.968
201709 0.701 104.100 0.782
201712 0.665 104.500 0.739
201803 0.704 105.300 0.776
201806 0.792 104.900 0.876
201809 0.946 106.600 1.030
201812 0.783 106.500 0.853
201903 0.893 107.700 0.962
201906 1.069 107.700 1.152
201909 0.925 109.800 0.978
201912 1.128 111.200 1.177
202003 0.970 112.300 1.002
202006 1.264 110.400 1.329
202009 1.042 111.700 1.083
202012 0.821 111.500 0.855
202103 1.168 112.662 1.203
202106 1.087 111.769 1.129
202109 0.751 112.215 0.777
202112 1.087 113.108 1.115
202203 2.170 114.335 2.203
202206 0.993 114.558 1.006
202209 1.056 115.339 1.063
202212 0.691 115.116 0.697
202303 0.810 115.116 0.817
202306 0.932 114.558 0.944
202309 1.045 115.339 1.052
202312 0.691 114.781 0.699
202403 0.936 115.227 0.943
202406 0.903 114.781 0.913
202409 1.044 115.785 1.046
202412 1.457 114.893 1.472
202503 0.931 115.116 0.939
202506 2.072 114.907 2.093
202509 1.309 115.471 1.316
202512 1.511 115.832 1.514
202603 1.006 116.303 1.004
202606 2.128 116.056 2.128

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ¥4.28 mean?
Ningbo Menovo Pharmaceutical Co (SHSE:603538) has a Cyclically Adjusted Revenue per Share of ¥4.28 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Ningbo Menovo Pharmaceutical Co and its competitors.
Is Ningbo Menovo Pharmaceutical Co's Cyclically Adjusted Revenue per Share too high?
Ningbo Menovo Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is ¥4.28. Overall, Ningbo Menovo Pharmaceutical Co has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ningbo Menovo Pharmaceutical Co's Cyclically Adjusted Revenue per Share compare to ZTS?
Ningbo Menovo Pharmaceutical Co's Cyclically Adjusted Revenue per Share of ¥4.28 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Ningbo Menovo Pharmaceutical Co and its competitors. Ningbo Menovo Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is ¥4.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ningbo Menovo Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Ningbo Menovo Pharmaceutical Co (SHSE:603538) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥17.40, compared to a current price of ¥27.09 — trading 55.7% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ¥4.28. Ningbo Menovo Pharmaceutical Co's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Ningbo Menovo Pharmaceutical Co (SHSE:603538), the current Cyclically Adjusted Revenue per Share is ¥4.28 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ningbo Menovo Pharmaceutical Co (SHSE:603538) Overvalued in 2026?

Based on GuruFocus' analysis, Ningbo Menovo Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥27.09 is trading 55.7% above its estimated GF Value™ of ¥17.40. GuruFocus considers Ningbo Menovo Pharmaceutical Co to be Significantly Overvalued.

Key valuation signals for SHSE:603538:

  • Cyclically Adjusted Revenue per Share: ¥4.28
  • GF Value™: ¥17.40 vs. price of ¥27.09 (55.7% above fair value)
  • GF Score™: 74/100 with 4 warning signs

No single metric tells the full story. See the SHSE:603538 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ningbo Menovo Pharmaceutical Co Business Description

Address No.999,Yangfan Road, Room 1406, No.1, High-tech Zone, Ningbo, CHN, 315040
Ningbo Menovo Pharmaceutical Co Ltd is a China-based company is engaged in the research and development, pilot, production and sales of pharmaceutical intermediates, APIs and finished drugs. Its products line includes cardiovascular, central nervous, respiratory, anti-tumor, anti-infective, digestive system, geriatric diseases and anti-viral systems.
74GF Score

Get the complete analysis for SHSE:603538

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥27.09
Price
¥17.40
GF Value